Baseline Blood Indices and Prolonged Length of Hospital Stay

• Conditions: Hospitalism; Diabetes Mellitus, Type 2; COVID-19 Pneumonia
• Interventions: Diagnostic Test: Inflamatory biomarkers

• Registration Number: NCT05054283
• Lead Sponsor: Gulhane Training and Research Hospital

Brief Summary

During a pandemic, length of hospital stay (LOS) is critical to managing high patient volumes and preserves access to care related to non-COVID-19 for maintaining the healthcare system. Moreover, identification of prolonged hospital stay may allow physicians to reevaluate critical patients, focused delivery of specific interventions, and improve the efficiency of hospital care.

Furthermore, in previous recent studies, attention has been paid to patients with diabetes and COVID-19 infection may require a prolonged LOS. However, there is little evidence on prognostic factors associated with an extension of hospitalization in mild or moderate illness due to COVID-19 infection. Therefore, it is crucial to determine the most vulnerable patients with diabetes mellitus even if they have a non-severe COVID-19 infection during the pandemic.

We hypothesize that the clinically relevant inflammatory parameters may have an impact on LOS in older adults with diabetes and non-severe COVID-19 infection. Therefore, we aim to investigate whether baseline inflammatory parameters on admission hospitals as possible predictors of prolonged LOS in older adults with diabetes and non-severe COVID-19 infection during the pandemic.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-09
• Study First Submitted: 2021-09-14
• Study First Submitted QC: 2021-09-14
• Last Update Submitted: 2021-09-14
• Study First Posted: 2021-09-23
• Last Update Posted: 2021-09-23
• Study Start: 2021-10-01
• Primary Completion: 2021-11-01
• Study Completion: 2021-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• We included all hospitalized Covid-19 patients with diabetes mellitus according to the any established diagnosis prior to admission or American Diabetes Association guidelines for diagnostic criteria

Exclusion Criteria

• The patients with severe Covid-19 infection, secondary diabetes or type 1 diabetes mellitus were excluded.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Length of hospital Stay (prolonged)	Inflamatory biomarkers	The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.
Length of hospital Stay (normal)	Inflamatory biomarkers	The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.

Primary Outcome Measures

Name	Time	Method
Prolonged Length of hospital	at least 2 week	The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization.

Trial Locations

Locations (1)

Gulhane training and research hospital; 🇹🇷 Ankara, Turkey